Adenocarcinoma de sítio primário desconhecido

Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Mar;34(3):228-46.Texto completo  Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary).Texto completo

National Institute for Health and Care Excellence. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. Apr 2023 [internet publication].Texto completo

1. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004 May 1;100(9):1776-85.Texto completo  Resumo

2. Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Mar;34(3):228-46.Texto completo  Resumo

3. Lee MS, Sanoff HK. Cancer of unknown primary. BMJ. 2020 Dec 7;371:m4050. Resumo

4. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012 Apr 14;379(9824):1428-35. Resumo

5. Hemminki K, Bevier M, Hemminki A, et al. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012 Jul;23(7):1854-63.Texto completo  Resumo

6. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014 Aug 21;371(8):757-65. Resumo

7. American Cancer Society. Key statistics for cancers of unknown primary. ​2023 [internet publication].Texto completo

8. Ganesh B, Buragamadagu B, Baralo B, et al. Cancer of unknown primary site: a population-based analysis of demographics and all-cause mortality.​ Paper presented at: 2022 American Society of Clinical Oncology annual meeting. Jun 3-7, 2022. Chicago, IL. Health services research and quality improvement: abstract e18518. J Clin Oncol. 2022 Jun;40(16_suppl):e18518.Texto completo

9. Cancer Research UK. Cancer of unknown primary incidence statistics: cancer of unknown primary incidence by age. ​2021 [internet publication].Texto completo

10. Urban D, Rao A, Bressel M, et al. Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer. 2013 Sep 3;109(5):1318-24.Texto completo  Resumo

11. Cancer Research UK. Cancer of unknown primary incidence statistics: cancer of unknown primary incidence by sex and UK country. ​2021 [internet publication].Texto completo

12. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site?-a hypothesis. Med Hypotheses. 2002 Sep;59(3):357-60. Resumo

13. Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med. 2003 Aug;9(8):999-1000. Resumo

14. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003 Jun;3(6):537-49. Resumo

15. Li X, Shao Y, Sheng L, et al. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site. Cancer Med. 2021 Feb;10(3):974-88.Texto completo  Resumo

16. Kato S, Alsafar A, Walavalkar V, et al. Cancer of unknown primary in the molecular era. Trends Cancer. 2021 May;7(5):465-77.Texto completo  Resumo

17. Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020 Sep;17(9):541-54. Resumo

18. Varghese AM, Arora A, Capanu M, et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol. 2017 Dec 1;28(12):3015-21.Texto completo  Resumo

19. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003 Sep;39(14):1990-2005. Resumo

20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers [internet publication].​Texto completo

21. Leader M, Patel J, Makin C, et al. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology. 1986 Dec;10(12):1315-24. Resumo

22. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary).Texto completo

23. Losa F, Fernández I, Etxaniz O, et al. SEOM-GECOD clinical guideline for unknown primary cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):681-92.Texto completo  Resumo

24. Royal College of Pathologists. Cancer datasets and tissue pathways. Jan 2018 [internet publication].Texto completo

25. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005 May 15;11(10):3766-72.Texto completo  Resumo

26. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):3-8. Resumo

27. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev. 2009 May;35(3):221-7. Resumo

28. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007 Sep;43(14):2026-36. Resumo

29. National Institute for Health and Care Excellence. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. Apr 2023 [internet publication].Texto completo

30. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007 May;18(5):945-9.Texto completo  Resumo

31. Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012 Apr 27;4(4):87-95.Texto completo  Resumo

32. Della-Fiorentina SA, Jaworski RC, Crandon AJ, et al. Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. Aust N Z J Surg. 1996 Feb;66(2):124-5. Resumo

33. Satoh F, Tsutusmi Y. Rare primary peritoneal mucinous adenocarcinoma in a 69-year-old man. Clin Case Rep. 2021 Sep;9(9):e04820.Texto completo  Resumo

34. Shah IA, Jayram L, Gani OS, et al. Papillary serous carcinoma of the peritoneum in a man: a case report. Cancer. 1998 Mar 1;82(5):860-6. Resumo

35. Diggs CH. Cancer of unknown primary site. Deciding how far to carry evaluation. Postgrad Med. 1989 Aug;86(2):186-91. Resumo

36. Zhu L, Wang N. 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. Surg Oncol. 2013 Sep;22(3):190-4. Resumo

37. Sève P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007 Jan 15;109(2):292-9.Texto completo  Resumo

38. Guerriero S, Alcazar JL, Ajossa S, et al. Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population. Int J Gynecol Cancer. 2010 Jul;20(5):781-6. Resumo

39. ClinicalTrials.gov. A phase II randomized study comparing the efficacy and safety of targeted therapy or cancer immunotherapy versus platinum-based chemotherapy in patients with cancer of unknown primary site (CUPISCO)​. NCT03498521. Mar 2023 [internet publication].Texto completo

40. Pauli C, Bochtler T, Mileshkin L, et al. A challenging task: identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience. Oncologist. 2021 May;26(5):e769-79.Texto completo  Resumo

41. Thomas SP, Jacobson LE, Victorio AR, et al. Multi-institutional, prospective clinical utility study evaluating the impact of the 92-gene assay (CancerTYPE ID) on final diagnosis and treatment planning in patients with metastatic cancer with an unknown or unclear diagnosis. JCO Precis Oncol. 2018 Nov;2:1-12.Texto completo  Resumo

42. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013 Jan 10;31(2):217-23.Texto completo  Resumo

43. Ding Y, Jiang J, Xu J, et al. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open. 2022 Apr;7(2):100407.Texto completo  Resumo

44. Rassy E, Bakouny Z, Choueiri TK, et al. The role of site-specific therapy for cancers of unknown of primary: a meta-analysis. Eur J Cancer. 2020 Mar;127:118-22. Resumo

45. Hermans KEPE, van den Brandt PA, Loef C, et al. Alcohol consumption, cigarette smoking and cancer of unknown primary risk: results from the Netherlands Cohort Study. Int J Cancer. 2021 Apr 1;148(7):1586-97.Texto completo  Resumo

46. Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005 Dec;12(12):1045-53. Resumo

47. Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):393-402. Resumo

48. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. Resumo

49. Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012 Nov;84(2):213-23. Resumo

50. Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009 Nov;35(7):570-3. Resumo

51. Lee J, Hahn S, Kim DW, et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer. 2013 Jan 15;108(1):39-48.Texto completo  Resumo

52. Gross-Goupil M, Fourcade A, Blot E, et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721-7.Texto completo  Resumo

53. Zarkavelis G, Mauri D, Pentheroudakis G. How I treat cancers of unknown primary. ESMO Open. 2019 May 10;4(suppl 2):e000502.Texto completo  Resumo

54. de Bresser J, de Vos B, van der Ent F, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010 Feb;36(2):114-9.Texto completo  Resumo

55. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018 Jan 18;378(3):230-40.Texto completo  Resumo

56. Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022 May 1;157(5):374-83.Texto completo  Resumo

57. Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2019 Jun 1;37(16):1380-90.Texto completo  Resumo

58. Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2006 Aug 1;24(22):3548-54.Texto completo  Resumo

59. Zhang P, Li J, Li J, et al. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study. Cancer. 2020 May 1;126 Suppl 9:2086-92.Texto completo  Resumo

60. Eads JR. Poorly differentiated neuroendocrine tumors. Hematol Oncol Clin North Am. 2016 Feb;30(1):151-62. Resumo

61. Hainsworth JD, Schnabel CA, Erlander MG, et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer. 2012 Jun;11(2):112-8. Resumo

62. Pouyiourou M, Wohlfromm T, Kraft B, et al. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. Eur J Cancer. 2021 Nov;157:179-89. Resumo

63. Kim CS, Hannouf MB, Sarma S, et al. Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada. Acta Oncol. 2015 Nov;54(10):1781-7.Texto completo  Resumo

64. Cancer.Net. Unknown primary: statistics. Mar 2023 [internet publication].Texto completo

65. Pavlidis N, Rassy E, Smith-Gagen J. Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. Int J Cancer. 2020 Mar 15;146(6):1490-8.Texto completo  Resumo

66. Mileshkin L, Bochtler T, Gatta G, et al. Cancer-of-unknown-primary-origin: a SEER-Medicare study of patterns of care and outcomes among elderly patients in clinical practice. Cancers (Basel). 2022 Jun 13;14(12):2905.Texto completo  Resumo

67. Cancer Research UK. Survival for cancer of unknown primary (CUP). May 2021 [internet publication].Texto completo

68. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005 Sep 1;23(25):5960-72.Texto completo  Resumo

69. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012 Dec 12;(12):CD003407.Texto completo  Resumo

70. Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019 May 20;37(15):1336-51.Texto completo  Resumo

71. Seymour L, Bogaerts J, Perrone A, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-52.Texto completo  Resumo

72. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016 Jul;62:132-7.Texto completo  Resumo